Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948078 | 1.00 | DPP4 (0.42) | DPP4LMNAALDH1A1MMP1MMP2 | |
| SCHEMBL5769336 | 0.85 | DPP4 (0.35) | DPP4LMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL5769339 | 0.85 | DPP4 (0.35) | DPP4LMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL15995187 | 0.84 | DPP4 (0.37) | DPP4LMNAALDH1A1MMP1MMP2 | |
| SCHEMBL19170142 | 0.81 | DPP4 (0.39) | DPP4LMNA | |
| SCHEMBL9873959 | 0.80 | CA12 (0.44) | DPP4LMNAALDH1A1SLC15A1CA12 | |
| SCHEMBL1619585 | 0.80 | DPP4 (0.47) | DPP4LMNAALDH1A1MMP1MMP2 | |
| SCHEMBL6201950 | 0.80 | CA12 (0.44) | DPP4LMNAALDH1A1SLC15A1CA12 | |
| SCHEMBL1619583 | 0.80 | DPP4 (0.47) | DPP4LMNAALDH1A1MMP1MMP2 | |
| Hydrochloric Acid SCHEMBL19136969 | 0.80 | DPP4 (0.38) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| EP-0794827-B1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-10 | — | — | EP | claimed |
| US-6090252-A | NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY | PHARMACIA BIOTECH AB (SE) | 2000-07-18 | — | — | US | claimed |
| EP-0794827-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | Pharmacia Biotech AB (SE) | 1997-09-17 | — | — | EP | claimed |
| WO-1996016724-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | PHARMACIA BIOTECH AB (SE) | 1996-06-06 | — | — | WO | claimed |
| EP-3013805-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS | EVOTEC INT GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-8927292-B2 | Methods of evaluating peptide mixtures | MOMENTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8921116-B2 | Methods of evaluating diethylamide in peptide mixtures for the preparation of glatiramer acetate | MOMENTA PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140080218-A1 | METHODS OF EVALUATING PEPTIDE MIXTURES | Momenta Phamaceuticals, Inc. (US) | 2014-03-20 | — | — | US | disclosed |
| CN-101959516-B | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2013-05-08 | — | — | CN | disclosed |
| CN-101959516-A | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2011-01-26 | — | — | CN | disclosed |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1633349-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2004098590-A1 | 4-BROMO-5- (2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (1-(AMINOCARBONYL) ETH-1-YL) AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-0794827-B1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2002-07-10 | — | — | EP | disclosed |
| US-6090252-A | NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY | PHARMACIA BIOTECH AB (SE) | 2000-07-18 | — | — | US | disclosed |
| EP-0794827-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | Pharmacia Biotech AB (SE) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996016724-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | PHARMACIA BIOTECH AB (SE) | 1996-06-06 | — | — | WO | disclosed |
| US-5026711-A | Prevention and treatment of cardiovascular disorders and infections states; anxiolytic and anti-allergic agents | SANOFI (FR) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038099-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | DPP4 1666/4885LMNA 1562/4885ALDH1A1 3054/4885 |
| US-20070161633-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, HRH2 | DPP4 3279/4885LMNA 1239/4885ALDH1A1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.